Promatix Biosciences

Promatix Biosciences is an oncology drug discovery company developing next-generation bispecific antibody-drug conjugates through data-driven target pairing.

Using a proteomics database and computational algorithms, the company identifies antigen combinations enabling selective tumour targeting, aiming to reduce off-tumour toxicity and improve treatment efficacy.

Its lead candidate, a bispecific conjugate for colorectal cancer, recently received Innovate UK grant funding to advance manufacturing scale-up and preclinical safety studies ahead of regulatory filing.